Laboratoires Thea: all 64 studies

Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Corneal Endothelium Health Following Articaine Ophthalmic Solution AdministrationNot yet recruitingNCT07838129Phase 4
• Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneNot yet recruitingNCT07796646Phase 2
• Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia ProgressionRecruitingNCT07522242Phase 2
• Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid SurgeryRecruitingNCT07234292
• Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®RecruitingNCT07206628
• A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal KeratoconjunctivitisRecruitingNCT07169695Phase 2
• Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)RecruitingNCT06891443Phase 3
• Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT06394973Phase 2Results posted
• Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.CompletedNCT06375499Not applicableResults posted
• Performance and Safety of T2769 in DEDCompletedNCT05965778Not applicableResults posted
• Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.CompletedNCT05931861Not applicableResults posted
• Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)TerminatedNCT05176717Phase 2/3Results posted
• Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)TerminatedNCT05158296Phase 2/3Results posted
• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis PigmentosaTerminatedNCT05085964Phase 2Results posted
• Extension Study to Study PQ-110-001 (NCT03140969)TerminatedNCT03913130Phase 1/2Results posted
• Efficacy of T2259 in DEDCompletedNCT03874429Not applicableResults posted
• Efficacy, Safety of T2769 in Dry Eye DiseaseCompletedNCT03830359Not applicableResults posted
• Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT03825380Phase 3Results posted
• Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneCompletedNCT03140969Phase 1/2Results posted
• Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated CrosslinkingCompletedNCT02979054Not applicableResults posted
• Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT02278614Phase 3Results posted
• Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract SurgeryCompletedNCT02101359Phase 3Results posted
• Efficacy and Safety of T2762 and Vismed® in Dry Eye SyndromeCompletedNCT02023268Phase 3Results posted
• Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit DoseCompletedNCT02017327Phase 4Results posted
• Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal UlcerCompletedNCT01794312Phase 3Results posted
• Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye SyndromeCompletedNCT01568593Phase 3Results posted
• Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT01494753Phase 2Results posted
• Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT01156012Phase 3Results posted
• Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.CompletedNCT01155999Phase 3Results posted
• Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.CompletedNCT01155219Phase 4Results posted
• Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With BlepharitisCompletedNCT01089608Phase 2Results posted
• A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS StudyCompletedNCT07234318
• Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye DiseaseCompletedNCT07007702
• New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry EyeCompletedNCT06903741Not applicable
• Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneActive, not recruitingNCT06627179Phase 2
• Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy VolunteersCompletedNCT05729594Phase 1
• Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy VolunteersCompletedNCT05622435Not applicable
• Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous PatientsCompletedNCT05397600Phase 3
• Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.Active, not recruitingNCT05389267Phase 1/2
• Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.CompletedNCT04898387Phase 3
• Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily TreatmentCompletedNCT04803240
• Efficacy and Tolerability of Blephademodex WipesCompletedNCT04780165Not applicable
• Macula Evolution in Patients With AMD Taking Oral Food SupplementationCompletedNCT04778436Not applicable
• Gastrointestinal Tolerance Assessment of T2309CompletedNCT04596605Not applicable
• Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of GlaucomaCompletedNCT04552964Not applicable
• Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye SyndromeTerminatedNCT02617095Not applicable
• Management of Eyelid Disorders by Ophthalmologists in Usual Medical PracticeCompletedNCT01552174
• Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops VialsWithdrawnNCT01546012Not applicable
• Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic ConjunctivitisCompletedNCT01344083Phase 2
• Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis PatientsCompletedNCT01203540Phase 4
• Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid TherapyCompletedNCT01190397Phase 1
• Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface DiseasesCompletedNCT01189474Phase 4
• Efficacy and Safety of GV 550 in Acute Adenovirus KeratoconjunctivitisCompletedNCT01156025Phase 2
• Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface DiseasesCompletedNCT01091311Phase 4
• Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy VolunteersCompletedNCT01086943Phase 1
• Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial ConjunctivitisCompletedNCT00357773Phase 3
• Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy VolunteersCompletedNCT00357539Phase 1
• Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy VolunteersCompletedNCT00357383Phase 1
• Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy VolunteersCompletedNCT00357292Phase 1
• Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye SyndromeCompletedNCT00357201Phase 2
• Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal KeratoconjunctivitisCompletedNCT00357019Phase 4
• Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy VolunteersCompletedNCT00356850Phase 1
• Azithromycin Level in Tears and in Conjunctiva in 36 Healthy VolunteersCompletedNCT00356772Phase 1
• Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of TrachomaCompletedNCT00356720Phase 3

← Laboratoires Thea overview and focus areas